Alex Goldberg

Amgen Inc. (NASDAQ:AMGN) and Splunk, Inc. (NASDAQ:SPLK) Added to Equity Profile Report's NASDAQ Decliners Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 02/14/2014 -- Equity Profile Report expands its NASDAQ Decliners Weekly Watch List adding Amgen Inc. (NASDAQ:AMGN) and Splunk, Inc. (NASDAQ:SPLK).

Amgen Inc. (NASDAQ:AMGN) a biotechnology medicines company that engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada is currently down (-0.43%) on 886,224 shares traded. Amgen Inc. (NASDAQ:AMGN) is currently down (-1.56%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about Amgen Inc. (NASDAQ:AMGN)

Splunk, Inc. (NASDAQ:SPLK) a company that provides software solutions that provide real-time operational intelligence is currently down (-0.78%) on 551,604 shares traded after Norse, Splunk Joint Webinar Showed Enterprises How to Maximize Splunk Security Investment with Integrated Dark Intelligence. Splunk, Inc. (NASDAQ:SPLK) is currently down (-3.1%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about Splunk, Inc. (NASDAQ:SPLK)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com